This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer

Core Insights - Pfizer plans to acquire a clinical stage biopharma company for up to $7 billion, targeting the weight-loss drug market [1] Company Strategy - The acquisition is part of Pfizer's strategy to enter the lucrative weight-loss drug market, which is currently dominated by Eli Lilly and Novo Nordisk [1]